Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.
Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.
At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.
Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.
Quanterix's product lineup is diverse and includes:
- Simoa platform
- Assay Kits
- LDTs & Assay Services
- Simoa p-Tau 217
- Simoa NfL LDT
- Simoa p-Tau 181 LDT
- HD-X Automated Immunoassay Analyzer
- SR-X Biomarker Detection System
- SP-X Imaging and Analysis System
- Simoa Accelerator Laboratory
- Homebrew - Custom Assay Development
- Uman NF-Light
The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.
Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.
Quanterix (NASDAQ: QTRX), a company specializing in ultra-sensitive biomarker detection, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. CEO Masoud Toloue and CFO Vandana Sriram will engage in a fireside chat on August 13, 2024, at 3:00 p.m. ET. The presentation will be accessible virtually, with registration available through a provided link. Following the conference, the presentation will be made available on Quanterix's website. This event offers an opportunity for investors and interested parties to gain insights into Quanterix's operations and future prospects in the field of scientific discovery through biomarker detection.
Quanterix (NASDAQ: QTRX), a company specializing in ultrasensitive biomarker detection, has announced its plans to report second quarter 2024 financial results. The company will host a conference call on Thursday, August 8, 2024, at 4:30 p.m. E.T. to discuss these results. Prior to the call, Quanterix will issue a press release detailing the Q2 2024 earnings after the market closes on the same day.
Investors can access the live webcast from the News & Events page within the Investors section of the Quanterix website. For those interested in participating, pre-registration links are available for both webcast and audio-only options. An archived webcast replay will be accessible on the company's website for one year following the call.
Quanterix (NASDAQ: QTRX) presented new data at the Alzheimer's Association International Conference (AAIC) demonstrating a novel multi-marker approach for Alzheimer's disease (AD) detection. This approach significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test while maintaining high accuracy above 90%. The multi-marker method combines p-Tau 217 with other AD-associated plasma biomarkers, including amyloid β 42, amyloid β 40, GFAP, and NfL, in an algorithm that provides a single risk score.
Key findings include:
- Reduced intermediate zone from 31.2% to 10.5% compared to p-Tau 217 alone
- Accurate amyloid classifications for 151 of 228 previously uncertain results
- Potential to provide diagnostic certainty for more patients
Quanterix plans to launch a multi-marker laboratory developed test later this year through its LucentAD product line.
Quanterix (NASDAQ: QTRX) has announced that its CEO, Masoud Toloue, and CFO, Vandana Sriram, will participate in the Scotiabank Healthcare 1x1 Day on June 20, 2024. Known for its ultrasensitive biomarker detection technology, Quanterix aims to showcase its advancements and strategies. For more details, visit their official website and explore their Simoa® technology.
Quanterix (NASDAQ: QTRX) announced the participation of its CEO Masoud Toloue and CFO Vandana Sriram at the 45th Annual Goldman Sachs Global Healthcare Conference. The company specializes in ultrasensitive biomarker detection to advance scientific discovery. The fireside chat presentation is scheduled for June 12, 2024, at 2:40 p.m. EST and will be webcast live. Replays will be available for a time post-conference. For more details, visit the Investor Relations section on Quanterix's website.
Quanterix (NASDAQ: QTRX), a leader in biomarker detection technology, announced that its CEO, Masoud Toloue, will participate in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for May 29, 2024, at 11:40 a.m. ET and will be available via a live webcast.
Replays will be accessible for a time post-conference. For more details, visit Quanterix’s official website.
Quanterix , a biomarker detection company, reported financial results for Q1 2024 with revenue of $32.1 million, a 12.7% increase year-over-year. The company is focused on developing new assays to detect neuro-pathologies like Alzheimer's, Parkinson's, and Multiple Sclerosis. Key highlights include the launch of a blood test for Alzheimer's and maintaining a strong cash position. The company reaffirmed its 2024 financial guidance with revenue expected in the range of $139 to $144 million.
Quanterix (NASDAQ: QTRX) will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results. The press release will be issued on May 7, 2024, after the market closes. Interested investors can access the webcast and dial-in information on the Quanterix website.
FAQ
What is the current stock price of Quanterix Corporation (QTRX)?
What is the market cap of Quanterix Corporation (QTRX)?
What is the core technology of Quanterix Corporation?
What are some applications of Quanterix's technology?
Who founded Quanterix Corporation?
What product platforms does Quanterix offer?
What makes Quanterix's diagnostic platform unique?
Is Quanterix publicly traded?
What significant achievements has Quanterix made recently?
What fluids can Quanterix's platforms detect biomarkers in?
Does Quanterix offer custom assay development?
What is the Simoa Accelerator Laboratory?
